Poniard Pharmaceuticals, Inc. (PARD)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0100 - Volume
7 - Avg. Volume
2 - Market Cap (intraday)
299,845 - Beta (5Y Monthly) -35.48
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Related News
Performance Overview: PARD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PARD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PARD
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.03%
Return on Equity (ttm)
-210.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.23M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.98M
Total Debt/Equity (mrq)
52.61%
Levered Free Cash Flow (ttm)
-4.53M
Research Analysis: PARD
Company Insights: PARD
PARD does not have Company Insights